BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/13/2015 10:38:00 AM | Browse: 976 | Download: 1875
Publication Name World Journal of Gastroenterology
Manuscript ID 15957
Country/Territory Australia
Received
2014-12-19 12:40
Peer-Review Started
2014-12-19 21:19
To Make the First Decision
2015-01-08 16:54
Return for Revision
2015-01-13 08:49
Revised
2015-01-27 12:53
Second Decision
2015-03-04 18:39
Accepted by Journal Editor-in-Chief
2015-03-05 01:19
Accepted by Company Editor-in-Chief
2015-03-12 16:31
Articles in Press
2015-03-12 16:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-04-16 10:56
Publish the Manuscript Online
2015-05-13 10:38
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Randomized Clinical Trial
Article Title Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab
Manuscript Source Invited Manuscript
All Author List Aflah Roohullah, Hui-Li Wong, Katrin M Sjoquist, Peter Gibbs, Kathryn Field, Ben Tran, Jeremy Shapiro, Joe Mckendrick, Desmond Yip, Louise Nott, Val Gebski, Weng Ng, Wei Chua, Timothy Price, Niall Tebbutt and Lorraine Chantrill
Funding Agency and Grant Number
Funding Agency Grant Number
Cancer Australia and the Cancer Institute New South Wales for the AGITG MAX Trial
Corresponding Author Aflah Roohullah, MBChB, FRACP, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Therry Road, Campbelltown NSW 2560, Australia. aflah.roohullah@sswahs.nsw.gov.au
Key Words Peritoneal neoplasms; Colorectal neoplasms; Bevacizumab; Intestinal perforation; Capecitabine
Core Tip This report is an analysis of three prospective studies including a randomized clinical trial. We analysed the rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving bevacizumab and systemic therapy. Previous reports had raised concerns regarding the risk of gastrointestinal perforation in this population. Our reports suggest that the absolute risk is not elevated and in addition clinicians appear to be confident in using bevacizumab in patients with colorectal cancer and peritoneal disease. We recommend that the presence of peritoneal disease is not a contraindication to the use of bevacizumab and systemic therapy.
Publish Date 2015-05-13 10:38
Citation Roohullah A, Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J, Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World J Gastroenterol 2015; 21(17): 5352-5358
URL http://www.wjgnet.com/1007-9327/full/v21/i17/5352.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i17.5352
Full Article (PDF) WJG-21-5352.pdf
Full Article (Word) WJG-21-5352.doc
Manuscript File 15957-Review.docx
Answering Reviewers 15957-Answering reviewers.pdf
Audio Core Tip 15957-Audio core tip.mp3
Biostatistics Review Certificate 15957-Biostatistics statement.pdf
Clinical Trial Registration Statement 15957-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form 15957-Conflict-of-interest statement.pdf
Copyright License Agreement 15957-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s) 15957-Clinical trial registration statement.pdf
Institutional Review Board Approval Form or Document 15957-Institutional review board statement.pdf
Peer-review Report 15957-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 15957-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 15957-Scientific misconduct check.pdf
Scientific Editor Work List 15957-Scientific editor work list.pdf